JBJavad Balasi

Javad Balasi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Javad Balasi has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Behcet’s disease; a narrative review with a focus on autoimmunity processes in involved organs

    by Zeynab Ebrahimi Fard, Javad Balasi, Atiyeh Kimiaefar, Kimia Jazi, Zahra Hajrezaei, Jafar Karami, Seyyed Mohsen Banitaba, Maryam Masoumi

    Behcet’s disease (BD) is an autoimmune and inflammatory disease that is mainly characterized by involvement of the gastrointestinal tract, cardiovascular system, genital tract and joints. The disease is more common in the Middle Eastern and Far Eastern countries and the frequency of recurrences and attacks varies among populations. Although the pathogenesis is not fully understood, there is evidence to suggest that immunodeficiency and specific patterns of production of immune regulatory mediators are important. Impaired autoimmune and inflammatory cells, target endothelial cells and prompt vasculitis in the involved organs. Elucidating the immunological mechanism of BD can facilitate the development of new therapies and therapeutic immunoregulatory interventions to prevent possible complications. New therapies, including manipulation of immune-regulating mediators such as interferon-alpha antagonists, have shown promising results in patients with BD. This review aims to consider the role of auto-inflammatory and autoimmune processes and related factors which give rise to the different manifestations of the disease in each involved organ.


  • Open Access

    Sleep Duration as the Main Indicator of Self-Rated Wellness and Health among Healthcare Workers Involved in the COVID-19 Pandemic

    by Maryam Masoumi, Kamyar Shokraee, Somayeh Mohammadi, Soroush Moradi, Mohammad Bagherzade, Javad Balasi, Abbas Smiley

    Objective: This study was performed during the COVID-19 pandemic to better understand the indicators of self-rated wellness and health among healthcare workers. Methods: Sleep pattern, mood status, nutritional condition, physical activity, habits and the subjective wellness and health index of the healthcare workers of a university affiliated hospital were surveyed. Paired t-tests were performed to compare the participants’ quality of life before and after the outbreak of COVID-19. Multivariable linear regression models with a backward elimination stepwise process determined the parameters that significantly correlated with self-reported wellness and health. Results: Of the 200 healthcare workers who participated in this study, 119 (60%) were female and 81 (40%) were male, with a mean (SD) age of 28.8 (5.9) years. We found that the COVID-19 pandemic significantly changed many lifestyle factors compared to the pre-pandemic states. The scores of sleep quality, mood status, pre-planned physical activity and social activity were reduced by 30%, 40%, 50% and 70%, respectively. The average night sleep duration before the pandemic was 7 h and 22 min, whereas during the pandemic it decreased to 6 h and 44 min, a debt of 38 min in sleep duration every night. As found by multivariable regression modelling, self-reported wellness and health before the pandemic period was associated with wake-up time, mood status, physical activity and diet. During the pandemic period, in addition to these variables, night sleep duration (β = 0.049, p = 0.049) and nap duration (β = 0.009, p = 0.01) were left in the final multivariable model and correlated significantly with the wellness and health index. Conclusion: COVID-19 has detrimentally affected healthcare workers’ well-being and quality of life. Sleep duration was the main factor correlated with subjective wellness and health index during the current COVID-19 pandemic.


  • Open Access

    Association of lifestyle and disease characteristics with self-rated wellness/health score in patients with rheumatoid arthritis

    by Reihane Tabaraii, Maryam Masoumi, Mahsa Bagherzadeh-Fard, Mohammad Amin Yazdanifar, Javad Balasi, Abbas Smiley

    Objective: To study the relationship of self-rated wellness/health and lifestyle in patients with rheumatoid arthritis. Methods: Self-rated wellness/health, demographics, smoking, mood, sleep, physical activity, diet, symptoms/signs, body mass index and laboratory findings in 142 patients with rheumatoid arthritis were collected in the current cross-sectional study. Multivariable generalized additive model (GAM) was employed to study the association of self-rated wellness/health score and lifestyle factors. Results: Female/male ratio was 116/26 and the mean (SD) age of sample was 52 (13) years. Mean (SD) self-rated wellness/health score out of 10 was 7.2 (1.63). Mean (SD) number of tender joints and swollen joints were 4.42 (4.55) and 4.00 (4.26), respectively. The mean sleep score was 29.5 out of 70. Patients went to bed more than one hour earlier during the weekdays compared to weekends (22:45 vs. 23:52 PM, respectively, p < 0.0001). They also woke up more than one hour earlier during the weekdays compared to the weekends (6:08 vs. 7:20 AM, respectively, p < 0.0001). Their nap duration during weekdays was about half an hour shorter than the nap duration on weekends (19.75 vs. 48.02 minutes, respectively, p < 0.0001). The mean mood and diet scores were 18.5/35 and 22.5/42, respectively. By backward elimination in multivariable regression model (GAM), disease duration, mood, sleep quality, weekdays sleep characteristics (sleep duration, time to go to bed, wake-up time, time to fall asleep and nap duration), and sleep duration on weekends remained in the final model (R2 = 0.225, p = 0.01). Sleep quality, nap duration on weekdays, night sleep duration on weekends and mood status were the significant variables associated with self-rated wellness/health score. Conclusion: In patients with rheumatoid arthritis, the low self-rated wellness/health score was associated with the low sleep quality, long sleep duration on weekends, and long nap duration on weekdays.


  • Open Access

    Effects of Immune System-Related Medications on COVID-19 Outcome in a Cohort of Iranian Patients: Preliminary Report of a Data Mining Study

    by Ehsan Bitaraf, Seyyed Amir Yasin Ahmadi, Alireza Gandomi-Mohammadabadi, Zahra Noorani Mejareh, Bahare Abdollahi, Javad Balasi, Farzan Moodi, Nima Hemmati, Ali Kabir

    Background. Regulation of the immune system is critical for fighting against viral infections. Both suppression and hyperactivity of the immune system result in failure of treatment. The present study was designed to show the effects of immune system-related medications on mortality and length of stay (LOS) in a cohort of Iranian patients with coronavirus disease 2019 (COVID-19). Methods. A data mining study was performed on 6417 cases of COVID-19 covered by 17 educational hospitals of Iran University of Medical Sciences, Tehran. Association of a researcher-designed drug list with death and LOS was studied. For death outcome, logistic regression was used reporting odds ratio (OR) with 95% confidence interval (CI). For LOS, right censored Poisson regression was used reporting incidence rate ratio (IRR) with 95% CI. Results. Among the corticosteroids, prednisolone was a risk factor on death ( , ). This association was increased after adjustment of age interactions ( , ) and was removed after adjustment of ICU admission interactions ( , ). Hydroxychloroquine showed a protecting effect on death ( , ); however, this association was removed after adjustment of age interactions ( , ). Among the antivirals, oseltamivir showed a protecting effect on death ( <g...


  • Open Access

    Side effects of methotrexate therapy in patients with rheumatoid arthritis

    by Maryam Masoumi, Javad Balasi, Seyed Mahdi Aghamiri, Soroush Moradi, Mahbube Baghban, Mostafa Vahedian, Alireza Gandomi-Mohammadabadi

    Introduction: Methotrexate is widely used as the most common disease-modifying anti-rheumatoid drug (DMARD) and is known as the first line treatment for rheumatoid arthritis (RA). Objectives: To assess the side effects of methotrexate in Iranian patients with RA and to compare them with the known side effects from previous studies. Patients and Methods: We conducted a cross-sectional study of 300 patients who fulfilled the EULAR 2010 criteria of RA. The following data were recruited from patients’ profiles; age, body mass index (BMI), duration of treatment with methotrexate, initiating dose, maximum dose and current dose of methotrexate, history of fatty liver disease or hepatitis B and concomitant use of sulfasalazine, leflunomide or hydroxychloroquine. Results: In 149 out of 300 patients (49.66%), Methotrexate therapy was stopped or tapered due to side effects including nausea (23%), flu-like symptoms (8%), hepatotoxicity (12%) and hair loss (6%). The patients with hepatotoxicity had a higher duration of treatment with methotrexate (10.35 compared with 5.83; PP=0.010). All of the RASS (rheumatoid arthritis severity scale) indexes including disease activity, functional impairment, and physical damage are related to the presence of hepatotoxicity (PConclusion: Methotrexate is an excellent and effective agent for the treatment of RA and its potential side effects during the treatment are dependent on the methotrexate dosage, the level of anti-citrullinated protein antibody (ACPA) and anti-MCV antibodies and concomitant use of other drugs such as leflunomide.


  • Correlation of clinical signs and symptoms of Behçet’s disease with platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR)

    by Soraya Shadmanfar, Maryam Masoumi, Fereydoun Davatchi, Farhad Shahram, Maassoumeh Akhlaghi, Seyedeh Tahereh Faezi, Hoda Kavosi, Amirhossein Parsaei, Soroush Moradi, Javad Balasi, et al.

    Behçet’s disease (BD) is a chronic disorder that involves multiple organs and is pathologically considered as a form of vasculitis. The current study aims to assess the metric properties of platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) in assessing BD disease activity. Three-hundred-nineteen patients with BD were enrolled in this cross-sectional study. Demographic and epidemiological data, including IBDDAM, time since the onset, and medication and manifestation history were recorded. Complete blood counts (CBC), NLR, and PLR were assessed by analyzing blood samples. On the last visit, patients were assessed for active manifestations of disease. IBDDAM and ocular IBDAAM scores were calculated for activity of disease in each patient. Both PLR and NLR were higher in patients with active BD (Mann–Whitney U test, p-value < 0.05). Patients with active ocular manifestation had significantly higher NLR and PLR (Mann–Whitney U test, p-value < 0.05). These ratios, however, were not associated with other active BD manifestations. A value of NLR > 2.58 had 46% sensitivity and 85% specificity for the diagnosis of active ocular manifestations (AUC: 0.690). NLR had a significant, though, weak positive correlation with IBDDAM (Spearman’s rho = 0.162; p-value < 0.05) and ocular IBDDAM (Spearman’s rho = 0.159; p-value < 0.05). Active Behçet’s presented with higher NLR and PLR ratios; however, there was only a modest correlation between NLR and BD activity (IBDDAM score). Also, NLR and PLR have significant relationship with ocular features of BD patients.


  • Open Access

    Side Effects of Azathioprine in Patients with Ocular Behçet’s Syndrome

    by Maryam Masoumi, Fereydoun Davatchi, Farhad Shahram, Maassoumeh Akhlaghi, Seyedeh Tahereh Faezi, Hoda Kavosi, Soraya Shadmanfar, Majid Alikhani, Soroush Moradi, Javad Balasi

    BackgroundBehçet’s syndrome (BS) is a multifactorial, polygenic, autoinflammatory vasculitis characterized by recurrent oral and genital ulcers, uveitis, skin lesions, and arthritis. Azathioprine has been well established as an effective therapy among other immunosuppressive drugs; however, concerns remain about its safety. This study was conducted to determine the types and prevalence of adverse events related with azathioprine in patients with ocular BS.MethodsWe carried out a cross-sectional study of 165 patients with a confirmed diagnosis of BS who had ocular involvement. Data were collected retrospectively on disease-related characteristics and events including severity, recurrence, relapse, recovery and flare-up, as well as on azathioprine dosage and the duration of use.ResultsOf 165 enrolled patients, 103 (62.43%) were male and 62 (37.57%) were female. Adverse events of treatment with azathioprine occurred in 11 patients (6.67%). These side effects included elevation of liver enzymes in 4 patients (2.43%), hypersensitivity reaction in 2 patients (1.21%), leukopenia in 2 patients (1.21%), nausea in 1 patient (0.61%), skin tumor in 1 patient (0.61%), and concomitant pancreatitis and hepatitis in 1 patient (0.61%). Six of these patients discontinued treatment, and 5 of them tapered the dose. In addition, we observed severe leukopenia in 2 patients.ConclusionAdministration of azathioprine with due attention to the signs, symptoms, and severity of the disease, results in a reduced rate of adverse events and resolution of the ocular involvement in patients with BS.

  • Serotype distribution of Streptococcus pneumoniae among healthy carriers and clinical patients: a systematic review from Iran

    by Maryam Alizadeh Chamkhaleh, Abdoulreza Esteghamati, Shirin Sayyahfar, Alireza Gandomi-Mohammadabadi, Javad Balasi, Hossein Abdiaei, Yousef Moradi, Maziar Moradi-Lakeh

    Streptococcus pneumoniae is associated with high morbidity and mortality in the world. Commercially licensed and available pneumococcal conjugate vaccines (PCVs) contain 10 (PCV10) and 13 (PCV13) pneumococcal serotypes. The most common serotypes of S. pneumoniae causing clinical diseases and carriers of S. pneumoniae in Iran are not yet known. Reviewing and reporting trends in the distribution of pneumococcal serotypes in Iran will be useful for policy-making as PCV is being introduced into Iran’s routine immunization program. Here, we report a systematic literature review of studies regarding S. pneumoniae serotype distribution in clinical and carrier patients in Iran. MEDLINE (via PubMed), Scopus, Embase, Ovid, Google Scholar, Web of Science, and the Iranian Database were used to identify relevant papers published from 1 January 2000 to 21 August 2019. The search returned 8 relevant articles. Among serotypes causing invasive pneumococcal diseases (IPD), serotype 23F (16.4%) was the most circulating serotype followed by 19F (15.2%), 19A (11.3%), 6A/B (9.2%), 9 V (5.8%), and 11A (5.14%). In carrier patients, the most common serotypes were, in rank order, 6A/B (10%), 19F (9%), 14(6.2%), 17F (4.8%), and 20(4.5%). Vaccine coverage among IPD patients would be 67.1% for PCV10-TT and 73.8% for PCV13. The present review demonstrates that the serotypes which were most responsible for disease in Iran are included in PCV10-TT and PCV13. However, sentinel surveillance must be continued in representative parts of the country to assess changing trends in the distribution of pneumococcal serotypes and their implications for vaccine selection and rollout in Iran.


  • Open Access

    Effect of Aminophylline in Preventing Renal Dysfunction among Neonates with Prenatal Asphyxia: A Clinical Trial

    by Maryam Saboute, Javad Balasi, Saleheh Tajalli, Mahmoud Hajipour, Shaghayegh Heshmat, Nasrin Khalesi, Leila Allahqoli

    Background: As there are different views on the effects of aminophylline on neonatal renal function, we intended to observe the effects of aminophylline on renal dysfunction in neonates with prenatal asphyxia.Methods: This randomized trial was conducted in the Obstetrics and Gynecology Hospital, Tehran, Iran, from June 2016 to May 2017, in neonates with moderate to severe asphyxia during birth. Fifty-six neonates were divided randomly into two groups. The intervention group received one dose of 5mg/kg slow intravenous aminophylline injection and the placebo group received 2 mL/kg of intravenous 10% solution of dextrose saline during the first hour of life. They were monitored and compared for renal functional indices, electrolytes, and complications of asphyxia during the three days of life.Results: The mean of Cr (37.9 ± 8.8 vs 38.5 ± 9.4 and 20.8 ± 4.8 vs 30.1 ± 5.2 μmol/L), GFR (21.55 ± 4.7 vs 20.25 ± 4.4 and 30.8 ± 7.1 vs 20.1 ± 6.5 mL/minute/1.73 m2 ), Na (135.1 ± 12.4 vs134.5 ± 11.2 and 128.9 ± 11.5 vs 134.2 ± 10.9 mEq/L), and urine output (98.2 ± 25 vs 96.8 ± 23 and 148.7 ± 35 vs 108.8 ± 20 cc) were in the aminophylline treated and placebo group on the 1st and 3rd days, respectively. The mean difference of Cr (-9.3 (-8.9; -9.7) μmol/L); (P= 0.02), GFR (10.7 (10.1; 11.3) mL/minute/1.73 m2 ) (P= 0.009), Na (-5.3 (-5.9; -4.7) mEq/L) (P= 0.002), and urine volume (39.9 (24.9; 54.9) cc) (P= 0.001) presented statistically significant differences on the third day between the intervention and placebo group.Conclusion: Aminophylline was effective in preventing renal dysfunction in neonates with asphyxia. Neonates who received aminophylline indicated a significant improvement in GFR and urine output on the first day of life.